OncoType Dx Breast Cancer Test at Chughtai Lab

OncoType Dx at Chughtai Lab

The OncoType Dx Breast Recurrence Score test is a revolutionary genomic assay that has transformed the therapeutic landscape for patients diagnosed with early-stage breast cancer. Offered through Chughtai Lab, Pakistan’s premier diagnostic network, this advanced molecular test analyzes the expression of 21 specific genes within tumor tissue to predict the likelihood of cancer recurrence and determine whether a patient will derive meaningful benefit from adjuvant chemotherapy. Unlike traditional genetic tests that evaluate a patient’s hereditary risk of developing cancer (such as BRCA1 or BRCA2 mutations), the OncoType Dx test is a somatic genomic assay. It interrogates the unique biology of the tumor itself, providing personalized, actionable insights that empower oncologists and patients to make highly informed treatment decisions.

By utilizing quantitative reverse transcription polymerase chain reaction (RT-qPCR) technology, the OncoType Dx assay measures the activity of 16 cancer-related genes and 5 reference genes. The resulting Recurrence Score (RS)—a number ranging from 0 to 100—categorizes patients into risk groups that dictate the optimal therapeutic pathway. For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer, this test is the clinical gold standard. It helps prevent both the over-treatment of patients who would not benefit from chemotherapy and the under-treatment of those with aggressive tumor biology who require systemic cytotoxic intervention. Chughtai Lab facilitates this sophisticated genomic testing by ensuring meticulous specimen handling, pathology verification, and secure international logistics to deliver world-class diagnostic accuracy to patients across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

• No Direct Patient Preparation Required: Because the OncoType Dx test is performed entirely on a previously retrieved tumor tissue specimen, patients do not need to undergo fasting, blood draws, or any direct physical preparation.
• Tissue Block Retrieval: The primary requirement is the submission of the patient’s formalin-fixed, paraffin-embedded (FFPE) tumor tissue block and the corresponding hematoxylin and eosin (H&E) stained pathology slide. This tissue is typically obtained during the patient’s initial diagnostic core needle biopsy, lumpectomy, or mastectomy.
• Pathology Report Submission: Patients must provide a copy of their original histopathology report, which details critical parameters such as tumor size, histological grade, estrogen receptor (ER) status, progesterone receptor (PR) status, and HER2 status.
• Clinical History Documentation: A completed clinical requisition form, signed by the treating oncologist, must accompany the specimen. This form outlines the patient’s age, menopausal status, nodal status, and planned therapeutic interventions.
• Specimen Integrity Verification: Chughtai Lab’s pathology team reviews the submitted tissue block to ensure it contains sufficient tumor volume and cellularity (ideally a minimum of 2 millimeters of invasive tumor content) before facilitating international transport.

During the Procedure

The diagnostic workflow for the OncoType Dx test at Chughtai Lab is a highly controlled, multi-step laboratory process designed to maintain specimen integrity and ensure analytical precision. Once the FFPE tissue block is received at a Chughtai Lab diagnostic center, a consultant pathologist performs a detailed microscopic review of the H&E slide. This step is critical to confirm the diagnosis of invasive breast cancer and to identify the area of the block with the highest density of tumor cells. If the tumor area is small, microdissection may be planned to enrich the sample and prevent dilution of the genomic signal by surrounding normal breast tissue or stromal elements.

Following local pathology verification, Chughtai Lab coordinates the secure, temperature-controlled international transport of the specimen to the centralized testing facility of Exact Sciences (the proprietary developer of the OncoType Dx assay). In the specialized molecular laboratory, total RNA is extracted from the paraffin-embedded tumor sections. The extracted RNA undergoes reverse transcription to synthesize complementary DNA (cDNA), which is then amplified and quantified using high-throughput quantitative real-time PCR. The expression levels of the 16 cancer-related genes are normalized against the 5 reference housekeeping genes to calculate the final Recurrence Score. The entire process, from specimen submission at Chughtai Lab to the generation of the comprehensive genomic report, is subject to stringent quality control measures to guarantee clinical validity.

When is an OncoType Dx Performed?

Hormone Receptor-Positive (HR+) Invasive Breast Cancer

The OncoType Dx test is indicated primarily for patients diagnosed with invasive breast cancer that expresses estrogen receptors (ER) and/or progesterone receptors (PR). Hormone receptor-positive breast cancers rely on hormones to grow, making them candidates for endocrine therapies like tamoxifen or aromatase inhibitors. However, the clinical behavior of HR+ tumors varies widely; some are indolent and highly responsive to endocrine therapy alone, while others possess aggressive genomic profiles that require chemotherapy. Physicians request the OncoType Dx test for HR+ patients to dissect this biological heterogeneity and determine if endocrine therapy alone is sufficient or if adjuvant chemotherapy must be added to the treatment regimen.

HER2-Negative Early-Stage Breast Cancer

A critical prerequisite for ordering the OncoType Dx assay is a confirmed HER2-negative status. HER2-positive breast cancers are biologically distinct, highly proliferative, and routinely treated with HER2-targeted therapies (such as trastuzumab) combined with chemotherapy, rendering the standard 21-gene recurrence score clinically inapplicable. For patients with HER2-negative tumors, the decision to administer chemotherapy is often challenging, especially when traditional clinicopathological features (like tumor size and grade) yield borderline or conflicting risk assessments. The OncoType Dx test provides the definitive molecular clarity needed to guide systemic therapy in this specific patient population.

Lymph Node-Negative or Limited Node-Positive Disease

The clinical utility of the OncoType Dx test is firmly established in patients with lymph node-negative (N0) invasive breast cancer. Additionally, robust clinical trial data (specifically the RxPONDER trial) has expanded its indication to include postmenopausal patients with limited lymph node-positive disease (1 to 3 positive axillary lymph nodes, N1). In these patients, the presence of micrometastases in the lymph nodes historically mandated chemotherapy. However, the OncoType Dx test helps identify a substantial subset of node-positive postmenopausal women who have low-risk genomic scores and can safely avoid the toxicities of chemotherapy, relying solely on endocrine therapy.

Determining the Benefit of Adjuvant Chemotherapy

One of the most compelling reasons physicians request the OncoType Dx test is to predict the absolute benefit of adjuvant chemotherapy. While chemotherapy is highly effective at destroying rapidly dividing cancer cells, it carries significant short-term and long-term toxicities, including myelosuppression, cardiotoxicity, neuropathy, cognitive decline, and secondary malignancies. By analyzing the expression of proliferation and invasion genes, the OncoType Dx test calculates whether the addition of chemotherapy to standard endocrine therapy will significantly reduce the patient’s risk of recurrence, allowing clinicians to spare low-risk patients from unnecessary toxicity while confidently prescribing it to high-risk patients.

Assessing the Risk of Distant Cancer Recurrence

The OncoType Dx test serves as a powerful prognostic tool by estimating the likelihood of distant breast cancer recurrence within 9 to 10 years of initial diagnosis, assuming the patient completes the recommended 5 years of adjuvant endocrine therapy. This prognostic insight is invaluable for both clinicians and patients, as it helps contextualize the overall gravity of the diagnosis. Understanding the quantitative risk of distant metastasis allows patients to actively participate in shared clinical decision-making, providing peace of mind to those with low-risk scores and reinforcing therapeutic compliance for those requiring aggressive multi-modality treatment.

What Does an OncoType Dx Detect?

The OncoType Dx Breast Recurrence Score test detects, quantifies, and analyzes several critical genomic and clinical parameters from the tumor tissue, including:

• Recurrence Score (RS): A precise, continuous numerical score from 0 to 100 that reflects the overall genomic risk of distant recurrence.
• Low Recurrence Score (RS 0-25): Indicates a low risk of distant metastasis and predicts no significant clinical benefit from the addition of adjuvant chemotherapy in postmenopausal women.
• High Recurrence Score (RS 26-100): Indicates a high risk of distant recurrence and predicts a substantial, clinically meaningful benefit from adjuvant chemotherapy.
• Quantitative Estrogen Receptor (ER) Expression: Measures the exact level of ESR1 gene expression, confirming the degree of hormone sensitivity at the molecular level.
• Quantitative Progesterone Receptor (PR) Expression: Quantifies PGR gene expression, which serves as a key indicator of a functional estrogen receptor pathway and favorable prognosis.
• Quantitative HER2 Expression: Measures ERBB2 gene expression to confirm HER2-negative status and rule out low-level HER2 amplification.
• Ki-67 Gene Expression: Evaluates the transcript levels of MKI67, a primary marker of cellular proliferation and tumor growth rate.
• STK15 Gene Expression: Measures Aurora Kinase A expression, reflecting mitotic spindle regulation and chromosomal instability.
• Survivin (BIRC5) Gene Expression: Quantifies anti-apoptotic signaling within the tumor cells, indicating resistance to programmed cell death.
• Cyclin B1 (CCNB1) Gene Expression: Assesses cell cycle progression markers, specifically those regulating the G2/M transition.
• MYBL2 Gene Expression: Measures transcription factor activity associated with high-grade tumor proliferation.
• Stromelysin 3 (MMP11) Gene Expression: Evaluates matrix metalloproteinase activity, reflecting the tumor’s capacity for extracellular matrix degradation and local invasion.
• Cathepsin L2 (CTSL2) Gene Expression: Quantifies lysosomal protease activity associated with tumor cell invasion and metastasis.
• Bcl2 Gene Expression: Measures an estrogen-regulated anti-apoptotic marker associated with more indolent tumor biology.
• SCUBE2 Gene Expression: Evaluates a co-expressed marker in the estrogen receptor pathway, correlating with favorable clinical outcomes.
• GRB7 Gene Expression: Measures growth factor receptor-bound protein 7, which is co-localized with HER2 and involved in cell migration.
• GSTM1 Gene Expression: Quantifies glutathione S-transferase mu 1 expression, reflecting cellular detoxification and drug resistance pathways.
• CD68 Gene Expression: Measures macrophage infiltration markers, providing insight into the inflammatory tumor microenvironment.
• BAG1 Gene Expression: Evaluates anti-apoptotic co-chaperone expression, which modulates glucocorticoid and estrogen receptor signaling.
• Reference Gene Normalization (ACTB, GAPDH, RPLP0, GUSB, TFRC): Verifies the consistent expression of five housekeeping genes to ensure the analytical validity of the assay.
• 9-Year Distant Recurrence Risk: Calculates the specific percentage probability of the cancer returning at a distant site within 9 years under endocrine therapy alone.
• Chemotherapy Benefit Percentage: Estimates the absolute reduction in recurrence risk (e.g., 3%, 5%, or >15%) achieved by adding chemotherapy.
• TAILORx Trial Alignment: Correlates the patient’s specific score with the landmark TAILORx trial outcomes for node-negative patients.
• RxPONDER Trial Alignment: Correlates the score with RxPONDER trial data to guide therapy in patients with 1-3 positive lymph nodes.
• Age and Menopausal Interaction: Highlights specific clinical nuances for premenopausal women aged 50 or younger who may benefit from chemotherapy even with intermediate scores (RS 16-25).

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing a seamless, highly professional experience for patients undergoing OncoType Dx testing. Because the OncoType Dx assay is a highly specialized genomic test performed at a centralized, accredited reference laboratory in the United States, the turnaround time reflects the complex logistics involved. Typically, the comprehensive genomic report is ready within 14 to 21 business days from the date the tissue specimen is received and verified at Chughtai Lab’s central pathology department in Lahore.

During this period, Chughtai Lab manages all aspects of international cold-chain logistics, customs clearance, and secure specimen tracking. Once the testing is complete, the official report is uploaded directly to the secure Chughtai Lab online portal. Patients and their referring oncologists can access, download, and print the high-resolution PDF report via the Chughtai Lab website or the dedicated mobile application. Additionally, physical copies of the report can be collected from any major Chughtai Lab diagnostic center across Pakistan, ensuring convenient access to these life-altering diagnostic insights.

OncoType Dx Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Recurrence Score (RS)	Low Score (0 – 25); indicates low risk of distant recurrence.	High Score (26 – 100); indicates high risk of distant recurrence.
Estrogen Receptor (ER) Expression	High quantitative expression (positive hormone receptor status).	Low or absent quantitative expression (reduced hormone sensitivity).
Progesterone Receptor (PR) Expression	High quantitative expression (indicates intact endocrine pathway).	Low or absent quantitative expression (associated with higher recurrence risk).
HER2 Expression	Low quantitative expression (confirms HER2-negative status).	Elevated quantitative expression (suggests HER2-positive biology).
Proliferation Group Genes	Low expression levels of Ki-67, STK15, Survivin, CCNB1, and MYBL2.	Elevated expression levels; indicates rapid tumor cell division.
Invasion Group Genes	Low expression levels of MMP11 and CTSL2.	Elevated expression levels; indicates high potential for tissue invasion.
9-Year Distant Recurrence Risk	Low percentage risk (typically <10% with endocrine therapy alone).	High percentage risk (often >20% without systemic chemotherapy).
Chemotherapy Benefit Prediction	No significant absolute benefit (<1% to 2% improvement).	Significant absolute benefit (often >10% to 15% risk reduction).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for OncoType Dx?

• Experienced Healthcare Professionals: Chughtai Lab features a highly qualified team of consultant pathologists who meticulously review and verify every tumor specimen before processing.
• Patient-Focused Care: Dedicated coordinators guide patients and families through the complex process of tissue block retrieval, documentation, and reporting.
• Quality Diagnostic Services: As one of Pakistan’s most trusted diagnostic networks, Chughtai Lab adheres to stringent international quality control standards.
• Professional Reporting: Comprehensive, easy-to-read genomic reports are delivered securely, providing clear therapeutic guidance for oncologists.
• Modern Diagnostic Approach: Chughtai Lab utilizes state-of-the-art specimen tracking and molecular pathology protocols to ensure sample integrity.
• Comfortable Environment: Patients and families receive compassionate, professional support at every step of their diagnostic journey.
• Convenient Location: With an extensive network of collection centers across Lahore, Karachi, Islamabad, and other major cities, accessing services is highly convenient.
• Commitment to Accurate Diagnosis: Chughtai Lab’s robust international logistics network ensures that specialized genomic assays like OncoType Dx are accessible to patients throughout Pakistan.